Accuracy of international guidelines for identifying significant fibrosis in hepatitis b e antigen-negative patients with chronic hepatitis

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 11, 2013, Pages

  Sanai, Faisal M ^a   Babatin, Mohammed A ^b   Bzeizi, Khalid I ^c   AlSohaibani, Fahad ^d   Al Hamoudi, Waleed ^a   Alsaad, Khaled O ^d   Al Mana, Hadeel ^e   Handoo, Fayaz A ^a   Al Ashgar, Hamad ^d   AlGhamdi, Hamdan ^a   Ibrahim, Abeer ^d   Aljumah, Abdulrahman ^a,e   Alalwan, Abduljaleel ^a,e   AlTraif, Ibrahim H ^a,e   Al Hussaini, Hussa ^f   Myers, Robert P ^g   Abdo, Ayman A ^a,g  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING FAHAD GENERAL HOSPITAL   (Saudi Arabia)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e Prince Sultan Military Medical City   (Saudi Arabia)

^f KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

Alanine Aminotransferase; Diagnosis; Fibrosis; HBV DNA; Hepatitis B; Liver Disease; Management; Sensitivity; Specificity

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B VIRUS DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES CRITERIA; ARTICLE; ASIAN PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER CRITERIA; CHRONIC HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER CRITERIA; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

AASLD; AFP; ALANINE AMINOTRANSFERASE; ALT; AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES; APASL; AREA UNDER THE RECEIVER OPERATING CHARACTERISTIC; ASIAN-PACIFIC ASSOCIATION FOR THE STUDY OF THE LIVER; ASPARTATE AMINOTRANSFERASE; AST; AUROC; CI; CONFIDENCE INTERVAL; DIAGNOSIS; EASL; EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER; FIBROSIS; HBEAG; HBSAG; HBV; HBV DNA; HEPATITIS B; HEPATITIS B E ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS; LIKELIHOOD RATIO; LIVER DISEASE; LR; MANAGEMENT; NEGATIVE PREDICTIVE VALUE; NPV; POSITIVE PREDICTIVE VALUE; PPV; SENSITIVITY; SPECIFICITY; ULN; UNITED STATES PANEL ALGORITHM; UPPER LIMIT OF NORMAL; USPA; Α-FETOPROTEIN;

ADULT; ALANINE TRANSAMINASE; BIOPSY; DNA, VIRAL; FEMALE; HEALTH SERVICES RESEARCH; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC;

EID: 84885841256     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.05.038     Document Type: Article

References (19)

1. Liaw Y.F., Kao J.K., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
2. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185. European Association for the Study of the Liver.
3. Keeffe E.B., Dieterich D.T., Han S.H., et al. Atreatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008, 6:1315-1341.
4. Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:1-36.
5. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001, 120:1828-1853.
6. Iloeje U.H., Yang H.I., Su J., et al. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group: predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
7. Sanai F.M., Helmy A., Bzeizi K.I., et al. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B. JViral Hepat 2011, 18:e217-e225.
8. Papatheodoridis G.V., Manesis E.K., Manolakopoulos S., et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?. Hepatology 2008, 48:1451-1459.
9. Kumar M., Sarin S.K., Hissar S., et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134:1376-1384.
10. Prati D., Taioli E., Zanella A., et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002, 137:1-10.
11. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
12. Komaroff A.L., Berwick D.M. Decision theory and medical practice. Principles of internal medicine 1983, 243-254. McGraw-Hill, New York. Update IV. K.J. Isselbacher, R.D. Adams, E. Braunwald (Eds.).
13. Göbel T., Erhardt A., Herwig M., et al. High prevalence of significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT in central Europe. JMed Virol 2011, 83:968-973.
14. Croagh C.M., Bell S.J., Slavin J., et al. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int 2010, 30:1115-1122.
15. Chen E.Q., Huang F.J., He L.L., et al. Histological changes in Chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal. Dig Dis Sci 2010, 55:432-437.
16. Cadranel J.F., Lahmek P., Causse X., et al. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis-results of a nationwide survey. Aliment Pharmacol Ther 2007, 26:565-576.
17. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areasunder two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
18. Papatheodoridis G.V., Chrysanthos N., Hadziyannis E., et al. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. JViral Hepat 2008, 15:434-441.
19. Feld J.J., Ayers M., El-Ashry D., et al. Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2007, 46:1057-1070.